Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CNR2 | P34972 | 4/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604840 | 0.93 | CNR1 (0.57) | CNR1ALDH1A1CNR2FAAHALOX12 | |
| SCHEMBL12722380 | 0.93 | CNR1 (0.57) | CNR1ALDH1A1CNR2FAAHALOX12 | |
| SCHEMBL2407680 | 0.91 | CNR1 (0.62) | CNR1ALDH1A1CNR2FAAHALOX12 | |
| SCHEMBL17790865 | 0.87 | CNR1 (0.71) | CNR1ALDH1A1CNR2FAAHALOX12 | |
| SCHEMBL29744529 | 0.85 | CNR1 (0.56) | CNR1ALDH1A1CNR2FAAHALOX12 | |
| SCHEMBL15700831 | 0.84 | CNR1 (0.64) | CNR1ALDH1A1CNR2FAAHALOX12 | |
| SCHEMBL18622736 | 0.82 | CNR1 (0.42) | CNR1ALDH1A1CNR2 | |
| SCHEMBL17790862 | 0.82 | CNR1 (0.45) | CNR1ALDH1A1CNR2FAAHALOX12 | |
| SCHEMBL17790888 | 0.82 | CNR1 (0.45) | CNR1ALDH1A1CNR2FAAHALOX12 | |
| SCHEMBL19328452 | 0.82 | CNR1 (0.45) | CNR1ALDH1A1CNR2FAAHALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013033602-A2 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | MILNE JILL C (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2012115695-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | FASN, FADS1, ELOVL5 | CNR1 1072/4885ALDH1A1 810/4885CNR2 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.